API SUPPLIERS

API Suppliers

0

US DMFs Filed

0

CEP/COS Certifications

0

JDMFs Filed

0

EU WC

0

Listed Suppliers

0

API REF. PRICE (USD / KG)

0

API Market Place

0

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

0

Europe

0

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Full Screen View

Biomunex Pharmaceutical

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Biomunex Pharmaceuticals Signs Strategic License and Co-Development Agreement with Onward Therapeutics for Bispecific Antibody Program

Details:

Biomunex and Onward will jointly develop, in a preclinical and early clinical program (BMX-101), a ‘first-in-class’ immunotherapeutic bispecific antibody, in hematological malignancies, developed by bi- and multi-specific antibody platform BiXAb.

Lead Product(s): BMX-101

Therapeutic Area: Oncology Product Name: BMX-101

Highest Development Status: PreclinicalProduct Type: Large molecule

Partner/Sponsor/Collaborator: Onward Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement February 16, 2021

ASK
US